Vector Pharma FZCO signs exclusive license and distribution rights to IXEMPRA in the Middle East 

Vector Pharma FZCO announced today the signing of an exclusive distribution agreement with R-PHARM US of Princeton, NJ . Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra(ixabepilone) in the Middle East & North African territories of Morocco, Tunisia, Algeria, Libya, Egypt, Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Lebanon, Jordan, and Iraq.

IXEMPRA (ixabepilone) is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

“I am honored to announce this regional agreement with R-Pharm US,” commented Vector Pharma FZCO Managing Director Samer Semaan. “Ixempra is an important therapy for patients with advanced breast cancer; the women across MENA will benefit from access to this therapy. Vector Pharma is thrilled to help make the product available throughout our territories to patients.”